Shark antibodies inspire optimization of human antibodies

May 15, 2014
This is a model of the nurse shark's immunoglobulin new antigen receptor molecule containing two stabilization principles, which could be transferred to human anitbodies to receive enhansed stability. Credit: Janosch Hennig, TUM/Helmholtz Zentrum

Genetically engineered antibodies are deployed successfully in cancer diagnostics and therapy. Therapeutic antibodies against Alzheimer's disease and multiple sclerosis are currently under development. An important criterion when designing suitable antibody fragments is their stability. Comparing the antibodies of sharks with those of humans, a team of researchers at the Technische Universitaet Muenchen and the Helmholtz Zentrum Muenchen discovered stabilizing mechanisms that can also be applied to optimize custom-tailored antibodies for medical applications.

Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.

A team of researchers headed by Dr. Matthias J. Feige and the professors Linda Hendershot of St. Jude Children's Research Hospital in Memphis (Tennessee, USA), Michael Sattler (Chair of Bimolecular NMR Spectroscopy at TU Muenchen and the Institute for Structural Biology at the Helmholtz Zentrum Muenchen), Michael Groll (Chair of Biochemistry at TU Muenchen) and Johannes Buchner (Chair of Biotechnology at TU Muenchen) set out to find new approaches for stabilizing antibodies by comparing mammalian antibodies with those of sharks.

Sharks have been in existence for over 500 million years. From an evolutionary perspective they are among the oldest animals with a "modern" immune system not unlike that of humans. Shark blood contains large quantities of urea, allowing the animal to survive in salt water. While urea protects sharks from dehydration, it can also destabilize sensitive protein molecules such as antibodies.

"Human antibodies would collapse under these conditions. Shark antibodies must, therefore, possess structural characteristics that make them particularly robust," says Matthias J. Feige, lead author of the publication. "We wanted to unravel this mystery."

Meticulous puzzle work

The researchers chose the IgNAR (immunoglobulin new antigen receptor) shark antibody for their investigations. Lacking structural information on the molecule and due to the fact that the molecule could not be completely crystallized, they developed a model of the antibody in detective-like puzzle work.

They crystallized parts of the antibody and determined their atomic structures using X-ray crystallography, comparing the segments with previously known structures of other immunoglobulins. For other antibody segments, they analyzed the structures using NMR spectroscopy. Time and again the researchers compared the determined structures and spatial distances with the results of X-ray diffraction measurements of natural shark antibody molecules to then finally construct a comprehensive model of the IgNAR antibody.

Precise examination of the protein's structure revealed that the Ig folding typical for antibodies had already developed over 500 million years ago, since it is also present in sharks. Moreover, the researchers were able to identify the source of the of shark antibody stability: It results from an additional salt bridge between structurally important amino acid chains and a particularly large non-polar nucleus of the Ig fold in shark antibodies.

Human antibodies with enhanced stability

The researchers succeeded in integrating both stabilizing principles into . In fact, the combination of both principles led to a significant increase of stability of the human antibody fragments. Their melting point was 10 degrees higher than that of the original molecule.

The increased stability also showed a positive effect in mammalian cells that typically produce : The altered antibodies were produced in significantly larger quantities. In the near future, so the expectation of the researchers, this insight will enable the development of improved therapeutic and diagnostic . They should become easier to fabricate and store, as well as remain active longer inside the human organism, allowing them to unfurl their full therapeutic potential.

Explore further: Engineered anti-toxin antibodies improve efficacy

More information: The structural analysis of shark IgNAR antibodies reveals evolutionary principles of immunoglobulins, Matthias J. Feige, Melissa A. Graewert, Moritz Marcinowski, Janosch Hennig, Julia Behnke, David Ausländerb, Eva M. Herold, Jirka Peschek, Caitlin D. Castro, Martin Flajnik, Linda M. Hendershot, Michael Sattler, Michael Groll, and Johannes Buchner, PNAS, Early Edition, 2014.

Related Stories

Engineered anti-toxin antibodies improve efficacy

January 9, 2014
The effectiveness of toxin-neutralizing antibodies is considered to be mediated through the interaction of the variable region of the antibody and the toxin; however, recent studies suggest that the constant region (Fc) of ...

Antibody builders

November 19, 2013
Antibodies are often the first line of defense against the body's invaders.  Built to recognize and attack foreign bacteria and viruses, antibody molecules are released by cells to do battle with microbial hostiles as part ...

Studies of cow antibodies help scientists understand how our own bodies work

February 18, 2014
Understanding how antibodies work is important for designing new vaccines to fight infectious diseases and certain types of cancer and for treating disorders of the immune system in animals and humans.

Novel antibodies for combating Alzheimer's and Parkinson's disease

December 3, 2012
Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type ...

Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014
Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.